CCAR2

Cell cycle and apoptosis regulator protein 2 · Q8N163 · CCAR2 on Sugi Atlas →

0 patent compounds predicted against CCAR2, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to CCAR2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer PHASE4UNKNOWN
Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin Lymphoma PHASE4UNKNOWN
Effect of Silymarin in Metastatic Colorectal Cancer Patients PHASE3UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Vorinostat in Children PHASE1/PHASE2COMPLETED
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer PHASE2COMPLETED
ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma PHASE2COMPLETED
Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer. PHASE2COMPLETED
Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis PHASE2COMPLETED
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma PHASE2COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers PHASE1COMPLETED
Nilotinib in Huntington's Disease PHASE1UNKNOWN
A Phase I, Open-Labeled, Single-Arm, Dose Escalation, Clinical and Pharmacology Study of Dichloroacetate (DCA) in Patients With Recurrent and/or Metastatic Solid Tumours PHASE1COMPLETED
Safety Study of Infusion of SGT-53 to Treat Solid Tumors PHASE1COMPLETED
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors PHASE1COMPLETED
Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction PHASE1COMPLETED
Assessment Of Long Noncoding RNA CCAT1 In Colorectal Cancer Patients nanUNKNOWN
The Effect of TRA-8 on Ovarian Cancer Tissue nanCOMPLETED
A Comparison of p53-induced Genes Activation in Patients With and Without Acute Myocardial Infarction nanCOMPLETED
Autophagy Bladder Cancer nanUNKNOWN
Chi-GVM Regimen for the Treatment of R/R PTCL nanUNKNOWN
Role of ADA SNPs in Subjects With Relapsing Multiple Sclerosis (RMS) nanUNKNOWN
Studying Cells Collected Through Ductal Lavage in Women Undergoing Surgery for Ductal Carcinoma In Situ or Other Breast Cancer nanCOMPLETED
Role of Sorcin and Annexin A3 in Breast Cancer Patients nanUNKNOWN
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients nanACTIVE_NOT_RECRUITING
Impact of CASP3 Gene in Chemoresistance nanNOT_YET_RECRUITING
Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CCAR2 binder may also engage these)

ProteinNameSimilarity
Q5R8S0 1.000 Q5R8S0 →
Q8VDP4 1.000 Q8VDP4 →
Q3UJB9 0.991 Q3UJB9 →
Q6PCQ0 0.991 Q6PCQ0 →
Q9Z136 0.990 Q9Z136 →
Q8N4X5 0.990 Q8N4X5 →
Q6P9Q6 0.990 Q6P9Q6 →
Q17R10 0.989 Q17R10 →
NFRKB Nuclear factor related to kappa-B-binding protein 0.989 landscape →
A0M8T5 0.989 A0M8T5 →
Q8K330 0.989 Q8K330 →
Q09YM8 0.989 Q09YM8 →
Q80TQ5 0.989 Q80TQ5 →
A1X157 0.989 A1X157 →
Q76LL6 0.988 Q76LL6 →
Q96ST8 0.988 Q96ST8 →
Q9EP53 0.988 Q9EP53 →
Q8IWE5 0.988 Q8IWE5 →
Q09YJ3 0.988 Q09YJ3 →
Q00PJ1 0.988 Q00PJ1 →
Q3T1I9 0.988 Q3T1I9 →
Q09YG9 0.987 Q09YG9 →
A1A4J7 0.987 A1A4J7 →
Q9CYA6 0.987 Q9CYA6 →
Q2IBF8 0.987 Q2IBF8 →
Q5T1M5 0.987 Q5T1M5 →
Q2IBD4 0.987 Q2IBD4 →
Q07E15 0.987 Q07E15 →
Q09YK4 0.987 Q09YK4 →
MAP3K9 Mitogen-activated protein kinase kinase kinase 9 0.987 landscape →